News
Lupin and AbbVie partner to develop hematological cancers drugs
Through this partnership, AbbVie gains exclusive global rights to develop and commercialize Lupin’s MALT1 inhibitors.
DBT releases Year End Review
DBT has released a detailed report on the key events, collaborations and achievements that took place in the year 2018.
Propanc Biopharma’s cancer treatment granted patent in India
“Building a robust patent portfolio has been a top priority in driving our drug development technology forward. Adding India to the growing list of countries where we have been granted patents reflects the strength of our growing IP portfolio for PRP,” said James Nathanielsz, Propanc’s Chief Executive Officer.
China’s HitGen Bayer enter DNA-encoded library-basedresearch collaboration
“Our research and development (R&D) platforms are supplemented by what we call an ‘open innovation’ model,” said Axel Trautwein, Head of Small Molecules, Crop Science division of Bayer. “HitGen’s experience in DNA-encoded chemistry fits that model well, and we look forward to using their advanced technology platform to develop solutions that help farmers control existing crop threats and get ahead of emerging ones.”
DBT announces Indo-Australian Biotechnology Fund call
Call for proposal is open from 14th December, 2018 to 23rd January, 2019
Exhibit in the 'India Pavilion' at BIO 2026
